GE HealthCare Technologies Inc.
Case Overview
| Status: | Status: Investigating |
| Company Name: | Company Name: GE HealthCare Technologies Inc. |
| Ticker: | Ticker: GEHC |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ:GEHC). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99, missing the consensus estimate of $1.05, and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15. CEO Peter Arduini said that “profitability in the first quarter was impacted by a PDx supplier issue that has since been resolved.” On this news, the price of GE HealthCare shares declined by $9.01 per share, or approximately 13%, from $68.50 per share on April 28, 2026 to close at $59.49 on April 29, 2026.
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99, missing the consensus estimate of $1.05, and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15. CEO Peter Arduini said that “profitability in the first quarter was impacted by a PDx supplier issue that has since been resolved.” On this news, the price of GE HealthCare shares declined by $9.01 per share, or approximately 13%, from $68.50 per share on April 28, 2026 to close at $59.49 on April 29, 2026.